ONC_SCCA 8093

Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)

This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Phase II
NCT01908101
Cancer
Breast
Jeanne Anderson MD
University of Washington
  • Alaska Research
  • Katmai Oncology Group